Trial Profile
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 23 Mar 2023 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.
- 23 Mar 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Dec 2023.
- 07 Jun 2022 Results assessing association of IO score and outcomes by using data from phase I part of this study presented at the 58th Annual Meeting of the American Society of Clinical Oncology